Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

The Food and Drug Administration has declared an end to the shortage of Novo Nordisk’s blockbuster ... sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the U.S. Food and Drug ...

Novo Nordisk (NVO) ended a five-day losing streak ... rating on the maker of hugely popular obesity/ diabetes drugs, Ozempic and Wegovy. Nine years after starting its coverage, the Paris-based ...